KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) Equity Ratio (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Equity Ratio for 16 consecutive years, with 0.81 as the latest value for Q4 2025.

  • Quarterly Equity Ratio rose 9.48% to 0.81 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.81 through Dec 2025, up 9.48% year-over-year, with the annual reading at 0.81 for FY2025, 9.48% up from the prior year.
  • Equity Ratio hit 0.81 in Q4 2025 for Arbutus Biopharma, up from 0.79 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.83 in Q4 2021 to a low of 0.68 in Q1 2025.
  • Historically, Equity Ratio has averaged 0.75 across 5 years, with a median of 0.76 in 2023.
  • Biggest five-year swings in Equity Ratio: increased 11.4% in 2021 and later decreased 15.49% in 2022.
  • Year by year, Equity Ratio stood at 0.83 in 2021, then fell by 15.49% to 0.7 in 2022, then rose by 4.84% to 0.73 in 2023, then rose by 0.69% to 0.74 in 2024, then increased by 9.48% to 0.81 in 2025.
  • Business Quant data shows Equity Ratio for ABUS at 0.81 in Q4 2025, 0.79 in Q3 2025, and 0.8 in Q2 2025.